Curcumin and its nano-formulation: The kinetics of tissue distribution and blood–brain barrier penetration

Tsai, Yin Meng; Chien, Chao Feng; Lin, Lie Chwen; Tsai, Tung Hu

doi:10.1016/j.ijpharm.2011.06.030

Cited by 457 publications

(302 citation statements)

References 40 publications

Supporting

Mentioning

282

Contrasting

Unclassified

Order By: Relevance

“…Several experiments including brain uptake quantification, confocal laser scanning microscopy, behavior studies, thera peutic efficacy of drugs and in vivo toxicity were carried out. The percentage NP uptake was calculated in the brain and expressed as percentage of dose administered per animal, and data was plotted over a 24-h time span [13,14,17,18,21,26,29,30,34,39] . In all cases, the brain weights of rat and mice used to convert % dose/g reported by some authors to % dose were 2 g and 400 mg, respectively [42] .…”

Section: In Vivo Studiesmentioning

confidence: 99%

“…Brain uptake of PLGA/PLA NPs (100 -300 nm) were tested at different doses, ranging between 0.02 and 5.25 mg/animal, by quantifying concentration of entrapped drug [13,14,29] or fluorescent marker [17,18,26,30,34,39] after administration to rats [13,14,17,18,30,34] or mice [26,29,39] (Figure 2 ). In all cases, the percentage of dose administered that was transported to the CNS was below 4 % , and the majority of the studies (7 out of 9 reported in this review) showed percentages lower than 1 % .…”

Section: Unmodified Plga/pla Npsmentioning

confidence: 99%

“…Curcumin-loaded PLGA NPs (163 nm) were found to have the lowest brain uptake (approx. 0.02 % ) according to quantification of drug level in the brain 1 h after intravenous administration [13] . When the level of entrapped drug was used as a measure to determine brain uptake of NPs, values lower than 0.17 % were reported [13,14] .…”

Section: Unmodified Plga/pla Npsmentioning

confidence: 99%

“…Among 29 papers cited in this review, 9 papers performed in vitro studies [20,23,24,31,33,37,38,40] , 8 papers focused on in vivo studies [13,15,16,18,21,25,27,30] , and 12 papers did both in vitro and in vivo studies [14,17,19,22,26,28,29,32,34,35,39,41] .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Sabliov

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

Abstract:The blood-brain barrier (BBB), which protects the central nervous system (CNS) from unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many therapeutic agents such as hydrophilic and macromolecular drugs cannot overcome the BBB. One promising solution is the employment of polymeric nanoparticles (NPs) such as poly (lactic-co-glycolic acid) (PLGA) NPs as drug carrier. Over the past few years, significant breakthroughs have been made in developing suitable PLGA and poly (lactic acid) (PLA) NPs for drug delivery across the BBB. Recent advances on PLGA/PLA NPs enhanced neural delivery of drugs are reviewed in this paper. Both in vitro and in vivo studies are included. In these papers, enhanced cellular uptake and therapeutic efficacy of drugs delivered with modified PLGA/PLA NPs compared with free drugs or drugs delivered by unmodified PLGA/ PLA NPs were shown; no significant in vitro cytotoxicity was observed for PLGA/PLA NPs. Surface modification of PLGA/PLA NPs by coating with surfactants/polymers or covalently conjugating the NPs with targeting ligands has been confirmed to enhance drug delivery across the BBB. Most unmodified PLGA NPs showed low brain uptake ( < 1 % ), which indirectly confirms the safety of PLGA/PLA NPs used for other purposes than treating CNS diseases.

show abstract

Section: In Vivo Studiesmentioning

confidence: 99%

Section: Unmodified Plga/pla Npsmentioning

confidence: 99%

Section: Unmodified Plga/pla Npsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Sabliov

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

show abstract

“…HPLC (high-performance liquid chromatography) was performed for the determination of Cur concentration (Tsai et al, 2011) (Song et al, 2011). Fifty microliters of serum was mixed with trichloroacetic acid (1.5 mg/mL) in acetonitrile 100 μL and centrifuged at 12,000 rpm at 4°C for 20 minutes.…”

Section: In Vivo Pharmacokinetic Studymentioning

confidence: 99%

Curcumin-loaded PLGA Nanoparticles Conjugated with Anti-P-glycoprotein Antibody to Overcome Multidrug Resistance

Punfa

Suzuki²,

Pitchakarn³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (21), 9249-9258 IntroductionMultidrug resistance (MDR) is a major problem for the success of cancer chemotherapy and is closely associated with treatment failure in the most common forms of cancer, including lung, colon, breast, and cervical cancer (Chang, 2003). Overexpression of P-glycoprotein (P-gp), a 170-kDa plasma membrane transporter, has been identified as one of the major causes of drug resistance in several cancers. P-gp belongs to the superfamily of ATP-binding cassette (ABC) transporters (Chang, 2003) that act as an ATP-dependent efflux pump and has a broad substrate specificity that includes xenobiotics (Bain et al., 1997), etoposide (Burgio et al., 1998), doxorubicin (Shen et al., 2008), vinblastine (Cisternino et al., 2004, and paclitaxel (PTX) (Jang et al., 2001;Gallo et al., 2003). Increased expression of P-gp, the product of the human MDR1 gene, is a well-characterized mechanism used by cancer cells to avoid the cytotoxic action of anticancer drugs. Based on decreases in intracellular drug accumulation by P-gp,

show abstract

Bioavailability and Bioactivity of Nanomaterial, Nano‐ and Microencapsulated Ingredients in Foods

Choi

2014

Nano‐ and Microencapsulation for Foods

View full text Add to dashboard Cite

Curcumin and its nano-formulation: The kinetics of tissue distribution and blood–brain barrier penetration

Cited by 457 publications

References 40 publications

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Curcumin-loaded PLGA Nanoparticles Conjugated with Anti-P-glycoprotein Antibody to Overcome Multidrug Resistance

Bioavailability and Bioactivity of Nanomaterial, Nano‐ and Microencapsulated Ingredients in Foods

Contact Info

Product

Resources

About